Federal · Amendment

Medical Devices Regulations updated: exclusions for certain drugs from in vitro diagnostic rules clarified

Medical Devices Regulations — under the FOOD AND DRUGS ACT

Recorded date: October 1, 2026
Detected: November 17, 2026. Verify commencement in the official source.

Health CareConsumer & Business

Plain-language summary · AI-assisted

The regulation that sets out which drugs are excluded from the in vitro diagnostic device rules has been restructured and updated. The previous single-sentence exclusion has been replaced with a clearer three-part list: (a) drugs listed in Schedule E or F of the Food and Drugs Act, (b) drugs listed in any schedule to the Controlled Substances Regulations (replacing the former references to multiple specific schedules and the Narcotic Control Regulations), and (c) drugs containing cannabis as defined under the Cannabis Regulations and Cannabis Act. The practical effect is a modernized reference to the Controlled Substances Regulations rather than the older patchwork of individual controlled drug schedules. Manufacturers and distributors of in vitro diagnostic products that also contain a drug should review whether their product falls within one of these three updated exclusion categories. This change was previously listed as a pending amendment and is now in force.

Who this affects
medical device manufacturers · in vitro diagnostic product manufacturers · Health Canada licence holders · regulatory affairs professionals in life sciences

Check the official text
SOR/98-282 on the official source ↗

This page isn't an official version of the law and isn't legal advice. Summaries may omit details. Verify the dates and provisions that apply to you against the official source.

View this law's change history · Follow this law by RSS

Keep up with what changes.

The free weekly digest brings together published changes across our coverage. Confirm your email to subscribe.